# Disruption of neutrophil homeostasis is associated with functional alterations in mitochondria of critically ill COVID−19 patients

**Authors:** Aya A. Elkhodiry, Basma A. Yasseen, Hajar El-sayed, Mona Zidan, Azza G. Kamel, Rehab Hamdy, Sara Gohar, Mohamed A. Badawy, Aya Saber, Hend E. El-Shqnqery, Omar Samir, Ahmed A. Sayed, Ashraf Eltaher, Hadeer Abdelkhalek, Mennatullah Eltaras, Malak W. ElBenhawi, Jantan Dawa, Marwa S. Hamza, Riem M. El-Messiery, Mohamed El Ansary, Engy A. Abdel-Rahman, Sameh S. Ali

PMC · DOI: 10.1038/s41598-026-38741-y · Scientific Reports · 2026-03-01

## TL;DR

This study shows that neutrophils in critically ill COVID-19 patients have altered mitochondrial function and calcium handling, which may contribute to disrupted immune balance.

## Contribution

The study reveals coordinated mitochondrial and calcium dysfunctions in neutrophils from critically ill COVID-19 patients, linking these to impaired neutrophil clearance.

## Key findings

- Critically ill patients showed increased immature neutrophils and reduced apoptosis compared to healthy controls.
- Neutrophils from ICU patients had hyperpolarized mitochondrial membrane potential and elevated mitochondrial ROS.
- miRNA-seq identified potential mortality-associated signatures, but these were not validated by functional readouts.

## Abstract

Understanding the molecular mechanisms underlying neutrophil dynamics during COVID−19 disease progression is essential for managing severe inflammatory conditions. We investigated whether alterations in neutrophil mitochondrial function and calcium handling are associated with disrupted neutrophil homeostasis in critically ill COVID−19 patients. We analyzed neutrophil counts, phenotypes, and apoptotic profiles in critically ill COVID−19 survivors (ICU-S) and non-survivors (ICU-NS) compared with healthy controls. Flow cytometry, metabolic profiling, immunofluorescence imaging, and small RNA sequencing (miRNA-seq) were used to characterize neutrophil apoptosis-related pathways and mitochondrial function in freshly isolated neutrophils. Critically ill COVID−19 patients showed marked neutrophilia and a higher proportion of immature CD16low neutrophils relative to controls. Both ICU-S and ICU-NS groups exhibited reduced neutrophil apoptosis, as evidenced by fewer annexin V+ cells and lower cleaved caspase−3 signal compared with healthy controls. Although exploratory miRNA-seq in a small subset of ICU patients identified differentially expressed miRNAs with predicted enrichment in apoptosis- and calcium-related pathways, these mortality-associated miRNA signatures were not corroborated by functional apoptosis readouts (cleaved caspase−3 and annexin V) between ICU-S and ICU-NS. Neutrophils from ICU patients also demonstrated altered calcium handling, hyperpolarized mitochondrial membrane potential, increased complex II–linked respiration, and elevated mitochondrial ROS relative to controls. Neutrophils from critically ill COVID−19 patients display coordinated alterations in calcium handling, mitochondrial activity, and apoptosis consistent with impaired neutrophil clearance and disrupted homeostasis. These findings are observational and do not establish causality; the miRNA results should be interpreted as hypothesis-generating rather than validated mortality biomarkers.

The online version contains supplementary material available at 10.1038/s41598-026-38741-y.

## Linked entities

- **Diseases:** COVID−19 (MONDO:0100096)

## Full-text entities

- **Genes:** EGLN1 (egl-9 family hypoxia inducible factor 1) [NCBI Gene 54583] {aka C1orf12, ECYT3, HALAH, HIF-PH2, HIFPH2, HPH-2}, GPD2 (glycerol-3-phosphate dehydrogenase 2) [NCBI Gene 2820] {aka GDH2, GPDM, mGDH, mGPDH}, MROS (Melkersson-Rosenthal syndrome) [NCBI Gene 8011] {aka MRS}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, MICU1 (mitochondrial calcium uptake 1) [NCBI Gene 10367] {aka CALC, CBARA1, EFHA3, MPXPS, ara CALC}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, EGLN3 (egl-9 family hypoxia inducible factor 3) [NCBI Gene 112399] {aka HIFP4H3, HIFPH3, PHD3}, CASP9 (caspase 9) [NCBI Gene 842] {aka APAF-3, APAF3, ICE-LAP6, MCH6, PPP1R56}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, CEACAM8 (CEA cell adhesion molecule 8) [NCBI Gene 1088] {aka CD66b, CD67, CGM6, NCA-95}, PPID (peptidylprolyl isomerase D) [NCBI Gene 5481] {aka CYP-40, CYPD}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, SDHB (succinate dehydrogenase complex iron sulfur subunit B) [NCBI Gene 6390] {aka CWS2, IP, MC2DN4, PGL4, PPGL4, SDH}, APAF1 (apoptotic peptidase activating factor 1) [NCBI Gene 317] {aka APAF-1, CED4}, ITPR3 (inositol 1,4,5-trisphosphate receptor type 3) [NCBI Gene 3710] {aka CMT1J, IMD132, IMD133, IP3R, IP3R-3, IP3R3}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, CCL14 (C-C motif chemokine ligand 14) [NCBI Gene 6358] {aka CC-1, CC-3, CKB1, HCC-1, HCC-1(1-74), HCC-1/HCC-3}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** tissue injury (MESH:D017695), hypoxia (MESH:D000860), Post-COVID pulmonary sequelae (MESH:D000094024), chronic diseases (MESH:D002908), mitochondrial dysregulation (MESH:D021081), hyperlactatemia (MESH:D065906), post-acute sequelae (MESH:D013313), ARDS (MESH:D012128), acute illness (MESH:D000208), NS (MESH:D056770), hypercoagulability (MESH:D019851), NET (MESH:C536657), calcium (MESH:D002128), COVID-ICU (MESH:C000711429), hypoxic (MESH:D002534), multi-organ dysfunction (MESH:D009102), autoimmune conditions (MESH:D001327), ICU (MESH:C000657744), lung injury (MESH:D055370), metabolic blood acidosis (MESH:D000138), asthma (MESH:D001249), leukocytosis (MESH:D007964), cardiovascular disease (MESH:D002318), infection (MESH:D007239), Cancer (MESH:D009369), COVID-19 (MESH:D000086382), lung damage (MESH:D008171), immune dysfunction (MESH:D007154), Diabetes (MESH:D003920), died (MESH:D003643), mitochondrial dysfunction (MESH:D028361), Neutrophilia (MESH:C563010), inflammation (MESH:D007249), thrombosis (MESH:D013927), critical illness (MESH:D016638), hypocalcemia (MESH:D006996), HBSS (MESH:D013651), NLR (MESH:D015467)
- **Chemicals:** 4',6-diamidino-2-phenylindole (MESH:C007293), sO2 (MESH:D013458), ACD (MESH:C002113), malate (MESH:C030298), creatinine (MESH:D003404), formaldehyde (MESH:D005557), D-glucose (MESH:D005947), insulin (MESH:D007328), Saponin (MESH:D012503), ROS (MESH:D017382), Calcium (MESH:D002118), FCCP (MESH:D002259), oligomycin (MESH:D009840), sodium hydroxide (MESH:D012972), Fluo-4 (MESH:C409648), Texas Red (MESH:C034657), glutaraldehyde (MESH:D005976), glutamate (MESH:D018698), Ascorbate (MESH:D001205), Paraformaldehyde (MESH:C003043), carbapenem (MESH:D015780), Antimycin A (MESH:D000968), Tetramethylrhodamine methyl ester (MESH:C401833), polypropylene (MESH:D011126), perchlorate (MESH:C494474), ATP (MESH:D000255), steroids (MESH:D013256), polystyrene (MESH:D011137), L-glutamine (MESH:D005973), CO2 (MESH:D002245), Rotenone (MESH:D012402), ADP (MESH:D000244), Triton-X (MESH:D017830), fluoroquinolone (MESH:D024841), uranyl acetate (MESH:C005460), R (MESH:D001120), remdesivir (MESH:C000606551), Alexa Fluor 750 (MESH:C502599), carbon (MESH:D002244), FITC (MESH:D016650), Hoechst 33342 (MESH:C017807), NH4Cl (MESH:D000643), EDTA (MESH:D004492), carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (MESH:C108897), oxazolidinone (MESH:D023303), Pluronic F-127 (MESH:D020442), hydroxychloroquine (MESH:D006886), HEPES (MESH:D006531), ivermectin (MESH:D007559), O (MESH:D010100), succinate (MESH:D019802), NaHCO3 (MESH:D017693), pyruvate (MESH:D019289), superoxide (MESH:D013481), D (MESH:D003903), MitoSOX (-), trypan blue (MESH:D014343), S (MESH:D013455)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** -19 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_5989)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953904/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12953904/full.md

## References

18 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953904/full.md

---
Source: https://tomesphere.com/paper/PMC12953904